📈 Economy · Next Month

Novo Nordisk A/S (NASDAQ: NVO) beats Q2 2026 adjusted EPS consensus of approx. $0.82 per ADS on August 5, 2026

Pending ✦ AI-generated prediction Published on 12. July 2026 · Predicted for 5. August 2026 · Based on: Historical Cycle

Probability

71%

Novo Nordisk reports Q2 2026 on August 5. The ADS EPS consensus stands at approximately $0.82 per TipRanks. GLP-1 demand for semaglutide (Ozempic/Wegovy) remains structurally strong; Novo benefits from global capacity expansion and growing reimbursements in Europe and the US. Competitive pressure from Eli Lilly (tirzepatide) is priced in. Novo has beaten EPS consensus in each of the last four quarters. Beat probability: 71%. Currency risk (DKK/USD, EUR/USD) could dampen USD ADS translation. No Polymarket market available.

Data basis for this prediction

TipRanks: NVO Q2-2026-EPS-Konsens ~0,82 USD ADS, Ergebnisdatum 05.08.2026
Trading Economics EUR/USD: 1,1416 am 12.07.2026 (Währungsrisiko DKK-Konversion beachten)
Novo Nordisk IR: Semaglutid-Kapazitätsausbaupläne 2025–2026; Ozempic/Wegovy globale Marktdaten

Note: This is an AI-generated statistical forecast for entertainment and information purposes. It does not constitute investment advice or a recommendation to buy or sell any financial instrument.

Verdict: Pending

This prediction is still open. It will be evaluated automatically against real-world sources after its due date.

Related Predictions

📈 Economy ✦ AI

Eli Lilly and Company (NYSE: LLY) beats Q2 2026 adjusted EPS consensus of approx. $8.83 per share on August 5, 2026

Eli Lilly reports Q2 2026 on August 5. Consensus stands at $8.81–8.85 adjusted EPS per TipRanks. In Q1 2026, Lilly beat by a remarkable 24.8% ($8.55 vs. $6.85 expected), driven by strong tirzepatide (Mounjaro/Zepbound) volumes and sustained GLP-1 demand. Manufacturing capacity was massively expanded in 2025–2026. Risks: US healthcare pricing pressure, potential rebate negotiations. Beat probability: 76%, as consensus estimates after a large Q1 beat tend to lag full ramp-up.

76%

Next Month · Predicted for 5. Aug 2026

📈 Economy ✦ AI

Citigroup (NYSE: C) beats Q2 2026 adjusted EPS consensus of approx. $2.68 per share on July 14, 2026

Citigroup reports Q2 2026 before market open on July 14. Wall Street consensus stands at $2.67–2.72 adjusted EPS per Alphastreet/Hudson Labs, implying roughly +35% YoY growth. The macro environment (elevated rates, strong trading revenues) structurally favored large US banks in H1 2026. JPMorgan, Goldman Sachs, and BofA are already listed as open beat-predictions for the same date; the historical beat rate in US large-cap banking over the last eight quarters exceeds 75%. No Polymarket market available; estimate based on sector analogues.

72%

Next Week · Predicted for 14. Jul 2026

📈 Economy ✦ AI

Wells Fargo (NYSE: WFC) beats Q2 2026 adjusted EPS consensus of approx. $1.72 per share on July 14, 2026

Wells Fargo reports Q2 2026 on July 14. Consensus stands at approximately $1.71–1.72 per Alphastreet, a YoY increase of ~7.5%. The bank benefits from still-elevated net interest margins and has made consistent cost progress. Balance sheet quality remained solid in Q1 2026. Slightly lower probability than Citi given regulatory overhangs and asset cap discussions. No Polymarket market available.

68%

Next Week · Predicted for 14. Jul 2026